Samsara backs ex-Gilead duo’s amalgamation of NASH, liver drug assets from former employer, other biopharmas

A new biotech just dropped with a basket of assets, including two clinical-stage ones, from Gilead, Shionogi, Phenex Pharmaceuticals, Astellas’ Mitobridge and Yale. The Palo Alto upstart is looking to treat severe metabolic disorders, such as NASH and type 2 diabetes. Leading the company is Mani Subramanian, who headed up…

...

Click to view original post